A metabolic associated fatty liver disease risk variant in mboat7 regulates toll like receptor induced outcomes

HIGHLIGHTS

• who: Jawaher Alharthi from the Ethics Ethics approval was obtained from the Sydney West Area Health Service, the University of Sydney, Human Research Ethics Committee (HREC/17/WMEAD/433)Written informed consent was obtained from all participants. have published the research work: A metabolic associated fatty liver disease risk variant in MBOAT7 regulates toll like receptor induced outcomes, in the Journal: (JOURNAL) of 13/Oct/2021
• what: The authors provide evidence that membrane bound O-acyltransferase domain containing 7 (MBOAT7) is a negative regulator of TLR signalling. The authors demonstrate that this is associated with . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.